Comparing the current results to its competitors, Galapagos Nv reported Revenue increase in the 4 quarter 2025 by 303.5 % year on year. The sales growth was above Galapagos Nv's competitors' average revenue growth of 7.93 %, achieved in the same quarter.
Galapagos Nv's Comment on Competition and Industry Peers
The company is exiting the cell therapy business to focus on new business development opportunities, with a priority on oncology and immunology and inflammation (I&I), while remaining open to other fields. It maintains a longstanding partnership with Gilead, which provides a strategic advantage globally. The competitive landscape includes risks related to patent protection and the potential for competitors to independently develop similar drugs or technologies. Competitors include Pfizer, with siltuximab (anti-IL-6); AstraZeneca, with anifrolumab (Saphnelo®, anti-IFN); and Argenx, with efartigimod (Vyvgart®, anti-FcRn), which may launch before the end of the decade. Many competitors possess significantly greater financial, technical, and human resources. Additionally, industry consolidation through mergers and acquisitions may increase competition.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Astria Therapeutics Inc's business model centers around developing and commercializing innovative therapeutics for various diseases and medical conditions.
Sources:
Galapagos Nv’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Galapagos Nv versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
